# Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

> **NCT00731549** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 1081 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Aripiprazole IM Depot

## Key facts

- **NCT ID:** NCT00731549
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-12
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 1081 (ACTUAL)
- **Last updated:** 2014-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731549

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731549, "Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00731549. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*